388 related articles for article (PubMed ID: 10761648)
1. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.
Doolittle ND; Miner ME; Hall WA; Siegal T; Jerome E; Osztie E; McAllister LD; Bubalo JS; Kraemer DF; Fortin D; Nixon R; Muldoon LL; Neuwelt EA
Cancer; 2000 Feb; 88(3):637-47. PubMed ID: 10649259
[TBL] [Abstract][Full Text] [Related]
3. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
4. Seizure-promoting effect of blood-brain barrier disruption.
Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
[TBL] [Abstract][Full Text] [Related]
5. Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82.
Zünkeler B; Carson RE; Olson J; Blasberg RG; Girton M; Bacher J; Herscovitch P; Oldfield EH
J Neurosurg; 1996 Mar; 84(3):494-502. PubMed ID: 8609564
[TBL] [Abstract][Full Text] [Related]
6. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
[TBL] [Abstract][Full Text] [Related]
9. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
10. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning.
Neuwelt EA; Specht HD; Howieson J; Haines JE; Bennett MJ; Hill SA; Frenkel EP
AJR Am J Roentgenol; 1983 Oct; 141(4):829-35. PubMed ID: 6412531
[TBL] [Abstract][Full Text] [Related]
11. The blood-brain barrier disruption controversy: does it hold water?
Ruffer JE; Glatstein E
Cancer J Sci Am; 1998; 4(2):84-5. PubMed ID: 9532409
[No Abstract] [Full Text] [Related]
12. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
13. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption.
Bhattacharjee AK; Nagashima T; Kondoh T; Tamaki N
Brain Res; 2001 May; 900(2):157-62. PubMed ID: 11334793
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors.
Miyagami M; Tsubokawa T; Tazoe M; Kagawa Y
Neurol Med Chir (Tokyo); 1990 Aug; 30(8):582-90. PubMed ID: 1703636
[TBL] [Abstract][Full Text] [Related]
15. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
16. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
17. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
[TBL] [Abstract][Full Text] [Related]
18. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption.
Marchi N; Fazio V; Cucullo L; Kight K; Masaryk T; Barnett G; Vogelbaum M; Kinter M; Rasmussen P; Mayberg MR; Janigro D
J Neurosci; 2003 Mar; 23(5):1949-55. PubMed ID: 12629200
[TBL] [Abstract][Full Text] [Related]
19. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Neuwelt EA; Hill SA; Frenkel EP
Neurosurgery; 1984 Sep; 15(3):362-6. PubMed ID: 6090973
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program.
Doolittle ND; Petrillo A; Bell S; Cummings P; Eriksen S
J Neurosci Nurs; 1998 Apr; 30(2):81-90. PubMed ID: 9642616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
